A phase II study of ixabepilone (BMS-247550) in patients with metastatic breast cancer previously treated with an Anthracycline and who are Taxane resistant
Phase 2
- Conditions
- Metastatic breast cancer
- Registration Number
- JPRN-jRCT2080220193
- Lead Sponsor
- Bristol-Myers K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 54
Inclusion Criteria
1. Diagnosis of histologically-confirmed, metastatic or advanced breast cancer. 2. Presence of at least one unidimensionally measurable disease. 3. No more than three prior chemotherapy regimens for metastatic disease. 4. Patients with metastatic breast cancer previously treated with an Anthracycline and who are resistant to Taxane. 5. Performance status 0 - 1.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: response rate, duration of observed response Safety: incidence rates and severity of observed adverse events
- Secondary Outcome Measures
Name Time Method